Shanghai Pharmaceuticals: B023 Cell Injection Approved for Clinical Trials.

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Pharmaceuticals Biotech has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its independently developed "B023 Cell Injection". B023 Cell Injection is a class I innovative biological product independently developed and produced by Shanghai Pharmaceuticals Biotech, with the core component being natural killer T cells. The clinical indications are unresectable, locally advanced or metastatic solid tumors that have failed standard treatment and have no effective treatment options. As of the date of the announcement, the project has accumulated approximately 39.2584 million RMB in research and development expenses. There are currently no drugs on the market worldwide with the same indication as this product.